---
title: "最高法院駁回了藥企試圖停止醫保價格談判的請求"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286922283.md"
description: "最高法院拒絕審理六家制藥公司對醫療保險藥品價格談判的上訴。預計這一決定將為患者節省 15 億美元，為醫療保險節省 60 億美元的第一年支出。下級法院的持續法律挑戰可能會導致未來的最高法院審查"
datetime: "2026-05-19T13:31:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286922283.md)
  - [en](https://longbridge.com/en/news/286922283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286922283.md)
---

# 最高法院駁回了藥企試圖停止醫保價格談判的請求

High court decision: The Supreme Court refused to hear petitions from six drugmakers challenging Medicare’s drug price negotiations. Projected savings: Negotiated prices are expected to save patients $1.5 billion and Medicare $6 billion in the first year. Legal battles continue: Separate lawsuits are still pending in lower courts, potentially setting up future Supreme Court review.

### 相關股票

- [BMY.US](https://longbridge.com/zh-HK/quote/BMY.US.md)
- [JNJ.US](https://longbridge.com/zh-HK/quote/JNJ.US.md)
- [PILL.US](https://longbridge.com/zh-HK/quote/PILL.US.md)

## 相關資訊與研究

- [華爾街看好嬌生：重磅新藥密集上市點燃增長預期](https://longbridge.com/zh-HK/news/286290087.md)
- [恆瑞醫藥與 BMS 達成 152 億美元戰略同盟 開啟「中國早研 + 全球轉化」思路](https://longbridge.com/zh-HK/news/286255133.md)
- [減肥神藥與華盛頓的權力迴廊｜藍血工廠](https://longbridge.com/zh-HK/news/286663213.md)
- [百時美施貴寶攜手中國藥企開展新藥研發，開啓全新跨國醫藥合作](https://longbridge.com/zh-HK/news/286589558.md)
- [ADHD 用藥「利他能」缺貨...網友疑考季因素 食藥署：藥廠早通知控貨中](https://longbridge.com/zh-HK/news/286754700.md)